利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

54 条记录 (耗时 0.029 秒)

    Peptide (VIRIP) which inhibits a circulating virus in humans and the use thereof
    31.
    发明授权
    Peptide (VIRIP) which inhibits a circulating virus in humans and the use thereof 失效
    抑制人类循环病毒的肽（VIRIP）及其用途

    公开(公告)号：US07037896B1

    公开(公告)日：2006-05-02

    申请号：US10111427

    申请日：2000-11-08

    申请人： Frank Kirchhoff ,  Jan Münch ,  Ludger Ständker ,  Wolf-Georg Forssmann

    发明人： Frank Kirchhoff ,  Jan Münch ,  Ludger Ständker ,  Wolf-Georg Forssmann

    IPC分类号： A61K38/16 ,  C07K7/08 ,  C07K2/00 ,  A61K38/00 ,  A61K38/02

    CPC分类号： C07K7/08 ,  A61K38/00

    摘要： A peptide having the following amino acid sequence: Z1-LEAIPMSIPPEVKFNKPFVF-Z2 (VIRIP) and its biologically active fragments and/or variants and/or derivatives, especially amidated, acetylated, sulfated, polyethylene glycol (PEG) modified, phosphorylated and/or glycosylated derivatives, and peptides obtainable by multiple synthesis which have the biological activity of VIRIP; wherein Z1 and Z2 are independently a sequence of from 0 to 10 amino acid residues, and if Z1 or Z2=zero amino acid residues, then Z1=H and/or Z2=COOH.

    摘要翻译： 具有以下氨基酸序列的肽：<？in-line-formula description =“In-line Formulas”end =“lead”？> Z 1 -leAIPMSIPPEVKFNKPFVF-Z 2 （VIRIP）<？in-line-formula description =“In-line Formulas”end =“tail”？>及其生物活性片段和/或变体和/或衍生物，特别是酰胺化，乙酰化，硫酸化，聚乙二醇 （PEG）修饰的，磷酸化和/或糖基化衍生物，以及可通过多重合成获得的具有VIRIP生物学活性的肽; 其中Z 1和Z 2独立地是0至10个氨基酸残基的序列，并且如果Z 1或Z 2 0个氨基酸残基，则Z 1 = H和/或Z 2 = COOH。

    Antibiotic peptides from bovine milk
    32.
    发明授权
    Antibiotic peptides from bovine milk 失效
    来自牛奶的抗生素肽

    公开(公告)号：US06579849B2

    公开(公告)日：2003-06-17

    申请号：US09155203

    申请日：1998-09-24

    申请人： Wolf-Georg Forssmann ,  Hans-Dieter Zucht ,  Manfred Raida ,  Knut Adermann ,  Hans-Jürgen Mägert

    发明人： Wolf-Georg Forssmann ,  Hans-Dieter Zucht ,  Manfred Raida ,  Knut Adermann ,  Hans-Jürgen Mägert

    IPC分类号： A61K3800

    CPC分类号： A23L3/3463 ,  A61K38/00 ,  C07K14/4732

    摘要： A peptide having the amino acid sequence H2N—X1—R—X3—X2—COOH  (formula I) wherein X1 is either zero or X1 and/or X2 are a residue representing at least five amino acid residues (symbolized in the one letter amino acid code), preferably naturally occurring amino acids, with the proviso that X1 and/or X2 contain at least one basic amino acid residue immediately followed by a hydrophobic amino acid residue and X1 and/or X2 contain at least one glutamine residue.

    摘要翻译： 具有其中X 1的氨基酸序列的肽是零或X 1和/或X 2是代表至少5个氨基酸残基的残基（在一字母氨基酸代码中表示），优选天然存在的氨基酸，条件是X 1和/或X 2 含有至少一个碱性氨基酸残基，紧接着是疏水性氨基酸残基，X 1和/或X 2含有至少一个谷氨酰胺残基。

    Process for preparing human relaxin-2
    34.
    发明授权
    Process for preparing human relaxin-2 有权
    人松弛素-2的制备方法

    公开(公告)号：US09434780B2

    公开(公告)日：2016-09-06

    申请号：US14234919

    申请日：2012-08-03

    申请人： Wolf-Georg Forssmann ,  Thomas Dschietzig ,  Ludger Ständker ,  Andreas Zgraja ,  Jochen Hirsch

    发明人： Wolf-Georg Forssmann ,  Thomas Dschietzig ,  Ludger Ständker ,  Andreas Zgraja ,  Jochen Hirsch

    IPC分类号： C07K14/64

    CPC分类号： C07K14/64 ,  Y02P20/55

    摘要： A process for preparing human relaxin-2 having the following amino acid sequence: A chain: (SEQ ID NO: 1) pGlu-Leu-Tyr-Ser-Ala-Leu-Ala-Asn-Lys-Cys-Cys-His- Val-Gly-Cys-Thr-Lys-Arg-Ser-Leu-Ala-Arg-Phe-Cys B chain: (SEQ ID NO: 2) Asp-Ser-Trp-Met-Glu-Glu-Val-Ile-Lys-Leu-Cys-Gly- Arg-Glu-Leu-Val-Arg-Ala-Gln-Ile-Ala-Ile-Cys-Gly- Met-Ser-Thr-Trp-Ser; comprising the following steps: providing the amino acids necessary for the synthesis of the A and B chains with usual protective groups, wherein the cysteines are employed as trityl-protected amino acids (L-Cys(Trt)-OH); effecting a chromatographic purification of the individual chains A and B after the solid state synthesis; followed by the simultaneous folding and combination of the individual chains A and B in ammonium hydrogencarbonate buffer at pH 7.9 to 8.4; and subsequent purification of the relaxin-2 formed.

    USE OF NATRIURETIC PEPTIDES FOR TREATING ANGIOEDEMA SYNDROMES
    38.
    发明申请
    USE OF NATRIURETIC PEPTIDES FOR TREATING ANGIOEDEMA SYNDROMES 有权
    用于治疗血管紧张素综合征的NATRIURETIC PEPTIDES的使用

    公开(公告)号：US20100204446A1

    公开(公告)日：2010-08-12

    申请号：US12733609

    申请日：2008-09-11

    申请人： Wolf-Georg Forssmann

    发明人： Wolf-Georg Forssmann

    IPC分类号： C07K14/58 ,  C07K14/575

    CPC分类号： A61K38/2242

    摘要： The present invention relates to the use of a natriuretic peptide, urodilatin, for treating patients suffering from acute drug induced angioedema, such as ACE inhibitor related adverse events. Preferably, a composition comprising an effective amount of urodilatin is intravenously administered to the patient continuously for 18 hours to 72 hours.

    摘要翻译： 本发明涉及利尿钠肽尿嘧啶苷用于治疗患有急性药物诱导的血管性水肿的患者，例如ACE抑制剂相关的不良事件。 优选地，将包含有效量的尿布菌素的组合物连续静脉内给药18小时至72小时。

    Human Chemokine HCC-1 Polypeptides To Improve Stem Cell Transplantation
    39.
    发明申请
    Human Chemokine HCC-1 Polypeptides To Improve Stem Cell Transplantation 审中-公开
    人趋化因子HCC-1多肽改善干细胞移植

    公开(公告)号：US20070244037A1

    公开(公告)日：2007-10-18

    申请号：US10577053

    申请日：2004-10-16

    申请人： Rudolf Richter ,  Reinhard Hen-Schler ,  Wolf-Georg Forssmann

    发明人： Rudolf Richter ,  Reinhard Hen-Schler ,  Wolf-Georg Forssmann

    IPC分类号： C07K14/52 ,  A61K38/19 ,  C07K16/00 ,  C12N1/00 ,  C12P21/00

    CPC分类号： A61K49/0008 ,  A61K38/00 ,  C07K14/523

    摘要： The invention discloses the human chemokine HCC-1, N-terminally truncated HCC-1 molecules and glycosylated HCC-1 which improve the homing of stem cells into the -bone marrow during stem cell transplantation. It is also provided a procedure for producing the polypeptides by recombinant techniques or chemical synthesis and for producing antibodies against such polypeptide. Furthermore, it is disclosed the modification of the polypeptide by coupling of amino acid residues and/or chemical groups or deleting amino-acids generating potent derivatives of the polypeptide. Another aspect of the invention provides a combination of the polypeptide of the present invention and a suitable pharmaceutical carrier for providing a therapeutically effective amount of the polypeptide for the treatment of various associated diseases. The invention concerns also the use of the HCC-1 molecules to increase engraftment of stem cells in the course of the stem cell transplantation performed in stem cell transplantation related diseases.

    摘要翻译： 本发明公开了人类趋化因子HCC-1，N-末端截短的HCC-1分子和糖基化的HCC-1，其在干细胞移植期间改善了干细胞归巢到骨髓中的归巢。 还提供了通过重组技术或化学合成生产多肽并产生针对这种多肽的抗体的方法。 此外，公开了通过偶联氨基酸残基和/或化学基团或删除产生多肽的有效衍生物的氨基酸来修饰多肽。 本发明的另一方面提供本发明的多肽和合适的药物载体的组合，用于提供治疗有效量的多肽用于治疗各种相关疾病。 本发明还涉及在干细胞移植相关疾病中进行的干细胞移植过程中使用HCC-1分子来增加干细胞的移植。